BRAF Inhibitor-Driven Tumor Proliferation in a KRAS-Mutated Colon Carcinoma Is Not Overcome by MEK1/2 Inhibition

被引：43
|
作者：
Andrews, Miles C. [1 ]
Behren, Andreas [2 ]
Chionh, Fiona [2 ]
Mariadason, John [2 ]
Vella, Laura J. [2 ]
Do, Hongdo [3 ]
Dobrovic, Alexander [3 ]
Tebbutt, Niall [1 ]
Cebon, Jonathan [1 ]
机构：
[1] Austin Hlth, Joint Ludwig Austin Oncol Unit, Melbourne, Vic, Australia
[2] Ludwig Inst Canc Res, Austin Branch, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 35期
关键词：
SQUAMOUS-CELL CARCINOMAS; ADVANCED MELANOMA; RAF INHIBITORS; MUTATIONS; SURVIVAL; V600E;
D O I：
10.1200/JCO.2013.50.4118
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：E448 / E451
页数：4
相关论文
共 50 条
  • [41] RETRACTED: The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib (Retracted Article)
    Song, Hao
    Zhang, Jinna
    Ning, Liang
    Zhang, Honglai
    Chen, Dong
    Pao, Xuelong
    Zhang, Kejun
    MEDICAL SCIENCE MONITOR, 2018, 24 : 3002 - 3010
  • [42] PHASE I/II STUDY OF FOLFIRI PLUS THE MEK1/2 INHIBITOR PIMASERTIB (MSC1936369B) AS SECOND-LINE TREATMENT FOR KRAS MUTATED METASTATIC COLORECTAL CANCER
    Macarulla, Teresa
    Tabernero, Josep
    Cervantes, Andres
    Rosello, Susana
    Van Cutsem, Eric
    Tejpar, Sabine
    Prenen, Hans
    Martinelli, Erika
    Troiani, Teresa
    Campana, Fank
    Laffranchi, Bernard
    Jego, Virginie
    von Richter, Oliver
    Ciardiello, Fortunato
    ANNALS OF ONCOLOGY, 2012, 23 : 27 - 27
  • [43] ING2 loss sensitizes KRAS-mutated NSCLC to WEE1 inhibition through regulation of CHK1 expression.
    Ricordel, Charles
    Thalappilly, Subash
    Archambeau, Jerome
    Chan, Angela
    Nixon, Nancy
    Desrues, Benoit
    Bebb, Gwyn
    Riabowol, Karl
    Pedeux, Remy
    MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 57 - 57
  • [44] Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244
    Ammoun, Sylwia
    Ristic, Natalia
    Matthies, Cordula
    Hilton, David A.
    Hanemann, C. Oliver
    NEUROBIOLOGY OF DISEASE, 2010, 37 (01) : 141 - 146
  • [45] Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer
    Vaishnavi, Aria
    Scherzer, Michael T.
    Kinsey, Conan G.
    Parkman, Gennie L.
    Truong, Amanda
    Ghazi, Phaedra
    Schuman, Sophia
    Battistone, Benjamin
    Garrido-Laguna, Ignacio
    McMahon, Martin
    CELL REPORTS, 2020, 32 (05):
  • [46] BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition
    Hofmann, Marco H.
    Gmachl, Michael
    Ramharter, Juergen
    Savarese, Fabio
    Gerlach, Daniel
    Marszalek, Joseph R.
    Sanderson, Michael P.
    Kessler, Dirk
    Trapani, Francesca
    Arnhof, Heribert
    Rumpel, Klaus
    Botesteanu, Dana-Adriana
    Ettmayer, Peter
    Gerstberger, Thomas
    Kofink, Christiane
    Wunberg, Tobias
    Zoephel, Andreas
    Fu, Szu-Chin
    Teh, Jessica L.
    Boettcher, Jark
    Pototschnig, Nikolai
    Schachinger, Franziska
    Schipany, Katharina
    Lieb, Simone
    Vellano, Christopher P.
    O'Connell, Jonathan C.
    Mendes, Rachel L.
    Moll, Jurgen
    Petronczki, Mark
    Heffernan, Timothy P.
    Pearson, Mark
    McConnell, Darryl B.
    Kraut, Norbert
    CANCER DISCOVERY, 2021, 11 (01) : 142 - 157
  • [47] Response to BRAF and MEK1/2 inhibition in a young adult with BRAF V600E mutant epithelioid glioblastoma multiforme: A Case Report and Literature Review
    Venkatesh, Ashwin
    Joshi, Amol
    Allinson, Kieren
    Das, Tilak
    Santarius, Thomas
    Jefferies, Sarah J.
    Harris, Fiona P.
    Jena, Rajesh
    Doherty, Gary J.
    CURRENT PROBLEMS IN CANCER, 2021, 45 (05)
  • [48] A phase 1b/2 trial of the PLK1 inhibitor onvansertib in combination with FOLFIRI-bev in 2L treatment of KRAS-mutated (mKRAS) metastatic colorectal carcinoma (mCRC)
    Lenz, Heinz-Josef
    Kasi, Anup
    Mendelsohn, Lawrence
    Cannon, Timothy Lewis
    Starr, Jason S.
    Hubbard, Joleen M.
    Bekaii-Saab, Tanios S.
    Ridinger, Maya
    Samuelsz, Errin
    Ruffner, Katherine L.
    Erlander, Mark G.
    Ahn, Daniel H.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [49] Trametinib Inhibition of MEK1 2 Upregulates PD-L1 Expression in KRAS-Mutant NSCLC Through ID1 Downregulation
    Puyalto, A.
    Rodriguez-Remirez, M.
    Lopez, I.
    Olmedo, M.
    Vilalta, A.
    Welch, C.
    Vicent, S.
    Calvo, A.
    Gil-Bazo, I.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S48 - S49
  • [50] Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras-Mutated Colorectal Cancer
    Tentler, John J.
    Nallapareddy, Sujatha
    Tan, Aik Choon
    Spreafico, Anna
    Pitts, Todd M.
    Morelli, M. Pia
    Selby, Heather M.
    Kachaeva, Maria I.
    Flanigan, Sara A.
    Kulikowski, Gillian N.
    Leong, Stephen
    Arcaroli, John J.
    Messersmith, Wells A.
    Eckhardt, S. Gail
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (12) : 3351 - 3362
12345